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Objective
To describe the direct and indirect costs of ambulatory and in-
patient treatments of heart failure during 2002, in the University
Hospital Antônio Pedro, Niterói.
Methods
A cross-sectional and retrospective study on utilization and
valuation of resources in 70 patients, consecutively selected,
under ambulatory and in-patient treatment. Questionnaires and
records of the patients were used for data collection. The resources
used were valuated in Brazilian Reais (2002). The study’s point
of view was the perspective from society. The data were analyzed
in the EPINFO program, 2002 version.
Results
The studied population consisted of 70 patients (39 women),
with average age of 60.3 years old. 465 in-patient days (28.5%
of the patients) took place. There were 386 ward hospitalizations
and 79 in ICUs. The cost with ambulatory appointments was
R$ 14.40. The expenses with ambulatory medications amounted
R$ 83,430.00 (R$ 1,191.86/patient/year). The cost per hospi-
talized patient was R$ 4,033.62. The cost with complementary
examinations totaled R$ 39,009.50 (R$ 557.28/patient/year).
Twenty patients retired due to heart failure, which represented a
loss in productivity of R$ 182,000.00. The total cost was R$
444,445.20. Hospitalization represented 39.7% and the use of
medications 38.3% from direct costs.
Conclusion
The hospitalization cost and the expenses with medications
represented the main components of direct costs. Indirect costs
represented economic impacts similar to direct costs.
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Heart failure is the major cause of hospitalization in Unified Health
System - Sistema Único de Saúde (SUS), from 65 years of age. The
prevalence of heart failure is ascending, arising out of the increase in
life expectancy of our population and a greater effectiveness of new
medications for the treatment, which extends life.
There are few national studies for the dimensioning of the
socioeconomic impact and epidemiology of heart failure. There is
the need for implementing economic methods to estimate the
costs, instead of simply incurring expenses with heart failure. The
estimate of the socioeconomic impact of the syndrome will provide
the health policy formulators with a greater base for decision-
making, before a scenario of lack of funds and need for prioritizing
in its allocation.
Stewart et al.1 did a study aiming at examine the cost of
heart failure in the United Kingdom and estimated that 988 thou-
sand individuals needed treatment in 1995.
The direct cost of health fund utilization for those patients
was estimated in $ 716 million pounds (US$ 1.136 billion), which
represented 1.83% from total expenses of National Health System
(NHS). Expenses with hospitalizations [$ 489.7 million pounds
(US$ 776 million)] and medications prescribed [$ 128.6 million
pounds (US$ 203 million)] represented 69 and 18% of those
expenses, respectively. The authors projected the costs for the
year 2000 and estimated that the total direct cost of heart failure
would reach $ 905 million pounds (US$ 1.436 billion), equivalent
to 1.91% from the total expenses of NHS.
Heart failure represents a great worrying for health care providers
in Sweden due to the increase of its prevalence and growing costs.
The estimated prevalence of heart failure in that country is approxima-
tely 2%2, and the cost for treatment and follow-up represents 2%
from the global health budget in the country. Heart failure is the
main hospitalization cause in patients > 65 years old and 75%
from the budget for that syndrome is spent with hospital and home
care. In 1996, the length of hospital stay varied between 3.5 to
9.5 (average of 6.5) days in different hospitals. The expenses with
medication refund increased from 8.4 to 14.9% of the total health
budget, from 1990 to 1997, which represented an absolute increase
of 81% in monetary terms. The cost of pharmacological treatment
in heart failure was estimated in 11% from the total cost for that
syndrome and ambulatory care represented 6% from the total cost
of the treatment.
Xuan et al.3 examined the economic impact and the standards
of treatment for heart failure in managed care population and
analyzed, retrospectively, the medical and pharmaceutical pro-
cedure request data. During the period of 1994, 378 patients
from 2.777 with heart failure diagnosis (14%) were admitted in
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hospitals, totaling an approximate cost of US$ 3 million, an average
of US$ 7.863 per hospitalized patient. From the studied population,
78% had medication prescriptions, with an average of US$ 942
per patient/year. Hospitalization represented 54% from the total
cost for heart failure treatment and medication prescription for
38% of the costs.
The objective of the present study was to estimate the direct
and indirect costs of ambulatory and in-patient treatment of heart
failure in SUS.
Methods
A cross-sectional retrospective study that estimated the use
and valuation of funds, in 12 months, in patients under ambulatory
follow-up of Cardiology of Universidade Federal Fluminense (UFF).
We elaborated questionnaires for the survey of demographic, so-
cioeconomic, clinical data, use of funds at Hospital Universitário
Antônio Pedro (HUAP), use of funds in other healthcare units.
The records of selected patients were reviewed with the aim of
quantifying the use of funds.
The study was approved by the Committee of Ethics in Re-
search from the College of Medicine of UFF and the participants
were clarified on the purpose of the study. They signed an informed
consent term.
The patients were over 18 years old, classified in C and D
stages of heart failure defined by the criterion of American Colle-
ge of Cardiology and American Heart Association.
Seventy consecutively selected patients were included, in ac-
cordance to the order of attendance in UFF ambulatory and inter-
viewed by a medical team trained for the task of application of
questionnaires.
Those costs directly resulting from interventions, specifically
cost from hospital admission, complementary examinations, me-
dications, professional fees, operational costs and transport of the
patient to the hospital, were calculated as direct costs.
The estimate of indirect costs was obtained through human
capital approach, in which the salary loss in 2002 was calculated
and expressed the human capital in monetary terms.
The study’s point of view was the perspective from society
regarding the economic impact of heart failure.
Costs in Brazilian Reais were attributed to the funds used,
values from 2002.
The respective operational cost (overhead) was attributed to
each hospital unit, based on a survey carried out by the Program
of Advanced Studies in Hospital and Healthcare System Adminis-
tration - Programa de Estudos Avançados em Administração Hospi-
talar e de Sistemas de Saúde of Universidade de São Paulo
(PROAHSA) in 40 public hospitals, in the states of São Paulo, Rio
de Janeiro and Minas Gerais that estimated the hospital cost
arrangement in such units4.
The valuation of ambulatory appointment considered fees of
the coordinating physician and the resident physicians, added by
the operational cost of HUAP. An operational cost (overhead) of
12% from the total costs of HUAP was attributed to the ambulatory
unit. In order to estimate the medical fee cost, the salary appor-
tionment was defined by the number of hours dedicated at the
ambulatory of heart failure by the residents and coordinator.
The hospital daily rate comprised the bed for the patient,
bedclothes, cleaning, hygienization of ward or ICU, hygiene care
of the patient, medication administration (orally or topic), and
control of vital signs, diuresis and weight.
For the estimate of daily costs of hospitalization, 3 patients
with syndrome diagnosis were prospectively analyzed. The objective
was to establish the use of resources, including medications and
complementary exams during the hospitalization, for the calculation
of the average value of hospital daily rate. An operational cost
(overhead) of 15.7% from the total of costs of HUAP was attributed
to the hospitalization unit.
The prices of medications were calculated through Brasíndice
table in the year 2002. For the presentations that had generic
medications, that modality was used. An adherence of 100% of
the patients was attributed to medicamentous treatment.
The values of complementary exams were obtained in the
List of Medical Procedures of Brazilian Medical Association,
reference values of 1999.
The data were compiled and reviewed in EPINFO program -
2002.
Results
The sample consisted of 70 patients with heart failure, 55.7%
females. The average age was 60.3 (variation from 34 to 90)
years old. Forty-two patients were white.
From the 70 interviewees, 47.1% belonged to functional
class I by the classification of New York Heart Association,
41.4% to functional class II, 8.5% to functional class III and
2.8% to functional class IV.
Concerning the etiology of heart failure, 30% had coronary artery
disease, 24.2% were with hypertensive cardiopathy, 27.1% showed
association of coronary artery disease and hypertensive cardiopathy,
11.4% had alcoholic etiology dilated cardiomyopathy, 4.2% from
sequels of rheumatic orovalvar disease, 1.4% with pericardial disease
and 1.4% with acyanotic congenital cardiopathy.
As for the education level, 20% were illiterate, 62.8% only
had the fundamental education and 17.1% had completed the
intermediate education.
The monthly family income was characterized by 12.8% in 1
minimum salary (R$ 200) range, 21.4% between 1 and 2 minimum
salaries (R$ 200 to R$ 400), 35.7% between 2 and 4 minimum
salaries (R$ 400 to R$ 800), 21.4% between 4 and 6 minimum
salaries (R$ 800 to R$ 1.200) and 7.1% over 6 minimum salaries
(> R$ 1.200). A patient reported he did not have his own and family
income, and was in the need for the help of others for his survival.
The patients attended, in the period of 12 previous months,
for ambulatory and urgency appointments, submission to comple-
mentary exams, hospitalization in HUAP or in other healthcare
units, in a total of 1,248 times (average of 17.8 patients/year).
The ambulatory appointments represented an average of six ap-
pointments per patient per year.
Twenty patients (28.5%) needed admission and/or readmission
in the last 12 months, amounting 386 daily rates in ward (average
of 19.3 days/patient/year, if we only consider hospitalized patients)
and 79 daily rates in intensive care units (average of 3.9 days/
patient/year, if we only consider hospitalized patients).
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The description of the number of medications used, in the
last 12 months, for ambulatory control of cardiopathy is on
table I, and the description of the number of complementary
exams performed in the last 12 months is on table II.
The estimate of unit cost, per ambulatory appointment, was
R$ 14.40. The patients were seen in the last 12 months, with
an average periodicity of two months, amounting a cost estimate
of R$ 6,048.00.
The ambulatory use medications were purchased by the pa-
tients, without any government subsidy, in the pharmacies and
drugstores in the city of Niterói. The total cost in the purchase of
ambulatory medications was R$ 83,430.00.
The estimate of total cost with complementary exams, added
by the operational cost of the hospital for their performance, was
R$ 39,009.50, with an estimate of average cost per patient per
year of R$ 557.28.
The estimated cost of hospital daily rate in ward was R$
139.54 and in ICU was R$ 250.58.
The estimate of total cost with hospitalization was R$
84,706.70 for the 386 days in ward and 79 days in ICU.
The estimate of average cost with hospitalization was R$
4,033.62/hospitalized patient in the year 2002.
The expenses with collective transport for patients and the
person with them to have an appointment, be hospitalized or
have complementary exams amounted R$ 11,580.80, representing
R$ 165.43 per patient/year. That total represented 2,496 and
1,264 return trips, respectively for patients and escorts.
The unit price of the journey was R$ 3.08, referring to the
average price of bus fare in the city of Niterói. All patients used
bus as transportation means.
The patients who worked (n=36), missed 772 working days
and had an average monthly income of 3.29 minimum salaries
in 2002, equivalent to R$ 658.00, which represented an amount
of R$ 21.93/day.
The escorts who had a regular job missed 1,037 working
days. That group had an average monthly income of 3 minimum
salaries (R$ 600.00) in 2002. Such income represented an amount
of R$ 20.00/day.
Twenty patients had an early retirement in consequence of
heart failure and had an average monthly income, before retire-
ment, of 3.5 minimum salaries (R$ 700).
Table III refers to the estimate of total costs in Brazilian Reais
for the 70 patients in the last 12 months of treatment.
Table I - Ambulatory medications used in the 12 months, by the patients with heart failure, followed-up in the cardiology ambulatory of HUAP
Ambulatory Absolute number of Average dose Monthly cost Total cost (R$)
medications patients using (mg/day) per patient (R$)
Captopril 45 100 35.84 19,353.60
Enalapril 10 20 16.37 1,964.40
Valsartan 5 80 33.79 2,027.40
Losartan 2 100 64.93 1,558.32
Furosemide 41 40 4.77 2,346.84
Hydrochlorothiazide 24 25 11.32 3,260.16
Spironolactone 21 25 13.29 3,349.08
Propranolol 26 80 6.55 2,043.60
Carvedilol 16 12.5 52.60 10,099.20
Metoprolol 2 150 10.72 257.28
Atenolol 5 25 3.78 226.80
Digital 25 0.25 7.47 2,241.00
Mononitrate 17 40 17.07 3,482.28
Propatylnitrate 3 10 10.58 380.88
Dinitrate 1 10 13.20 158.40
Hydralazine 4 50 4.12 197.76
Clonidine 4 0.15 3.49 167.52
Nifedipine 1 30 7.10 85.20
Amlodipine 7 5 37.03 3,110.52
Verapamil 5 240 21.10 1,266.00
Diltiazem 3 120 17.32 623.52
Acetylsalicylic acid 41 200 7.66 3,768.72
Ticlopidine 2 500 28.76 690.24
Clopidogrel 2 75 184.44 4,426.56
Amiodarone 2 200 15.85 380.40
Atorvastatin 1 10 90.07 1,080.84
Sinvastatin 19 10 28.43 6,482.04
Pravastatin 2 10 27.59 662.16
Gemfibrozil 2 600 49.69 1,192.56
Warfarin 8 5 11.72 1,125.12
Fenoterol/Ipatropium 2 15 ml 25.84 620.16
Formoterol/Budesonide 1 12 mcg/200 mcg 59.76 717.12
Aminophylline 1 200 4.37 52.44
Prednisone 1 5 9.28 111.36
Glibenclamide 5 5 5.33 319.80
Metformin 2 850 5.80 139.20
Glimepiride 2 2 30.96 743.04
Insulin 2 120U 44.84 1,076.16
Omeprazole 2 20 31.56 757.44
Ranitidine 4 150 11.80 566.40
Thiamin 2 300 13.28 318.72
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Discussion
The average age was 60.3 years old, similar to those in EPICA
Project-Niterói5 on the epidemiology of heart failure in Niterói,
carried out in 2001. In Framingham Heart Study6, the average
age at the appearance of heart failure was 65 years old. The
earliest age, in the sample of the city of Niterói, showed that the
population of public health system manifested the syndrome among
a younger and more productive age range, determining a greater
load of disease for the society, as demonstrated by the indirect
costs estimated in the studied sample.
Ratifying that hypothesis, Philbin et al.7, identified the socio-
economic status as determining for the development of heart failure
and qualified as an independent risk factor for hospital readmission
in the arising of heart failure.
The socioeconomic data of the patients revealed the low edu-
cation level, with 20% of illiterates and 62.8% with only fundamen-
tal education. Such low level of education can be a limiting factor
for the education of patients in self-care and compliance with
medical recommendations.
The monthly family income was concentrated in the range
from 2 to 4 minimum salaries (35.7%), showing a limited ability
of self-financing the necessary funds for the treatment, especially
the chronic use medications.
The high rate of admission and readmission, in the analyzed
length of time, is in accordance to the systematic review performed
by Berry et al.8, who reported that up to a third of the patients
are admitted within the first year after discharge.
The utilization profile of medications specified for the treatment
of heart failure showed a little frequent fact in the medical prac-
tice in the real world. In the studied sample, there was a great
adhesion to medications recommended in the treatment protocol
of Brazilian Cardiology Association. Such finding is not the usual
one, even in developed countries. In the Swedish study carried
out by Cline et al.9, only 24% of the sample used the IACE inhi-
bitor, despite all evidences available in medical literature demons-
trating the benefit of morbid-mortality with the use of that thera-
peutic class in patients with heart failure. Such unusual adhesion
to clinical protocols, recommended by the main cardiology asso-
ciations in the world, is attributed to the fact that HUAP is a
university hospital, where the evidence-based medicine practice
is directed to resident physicians, in the way of obtaining the
most from medicamentous benefit with the treatment of patients
with heart failure.
The estimate of unit cost, per ambulatory appointment, was
R$ 14.40. SUS refunded to HUAP, in 2002, the amount of R$
2.54 per cardiologic appointment, demonstrating the 82% diffe-
rence between the refund and the estimated cost of appointment.
The medications were financed, exclusively, by the patients
and their families, as there was not a free medication-supplying
program for them. The absence of a pharmaceutical assistance
policy in SUS at that time encumbered the patient, who bought
the medication from retailers, without discounts, becoming an
important determinant for descompensations of heart failure and
repeated hospital admissions due to the lack of continuity in the
pharmacological treatment, as there is frequently a disproportion
between the increase in the income of the patient and the increase
of prices of medications. EPICA Project-Niterói showed that the
abandonment of medicamentous treatment was the main reason
for hospital admission in SUS, in patients with heart failure.
The complementary exams were valuated by the List of Medical
Procedures of Brazilian Cardiology Association, version 1999. The
decision for the use of such values was based on technical difficulties
to carry out the costing of each complementary exam.
The estimate of coast per patient hospitalized in the last 12
months was R$ 4.033.62. SUS accounted the amount of R$
533.52 in 2002, for a total of 372.594 hospitalizations with a
main diagnosis of heart failure10. Such difference of values ex-
Table II - Complementary exams performed in the last 12 months
in patients with heart failure, followed-up in the cardiology
ambulatory of HUAP
Complementary Number of exams Unit cost Total cost
exams performed
Biochemical 281 21.00 5,901.00
Coagulogram 149 20.40 3,039.60
Lipidogram 37 21.00 777.00
Hepatic assessment 11 41.80 459.80
Cardiac enzymes 14 40.00 560.00
Hemogram 256 9.00 2,304.00
USE 9 5.40 48.60
Urine culture 4 15.00 60.00
Anti-HIV 1 45.00 45.00
Artery gasometry 4 20.10 80.40
Thyroid assessment 1 51.00 51.00
Serology for hepatitis 1 142.50 142.50
HbA1c 1 13.50 13.50
Thoracic radiography 114 16.00 1,824.00
Column radiography 1 17.50 17.50
Coronariography 10 435.00 4,350.00
Abdomen USG 3 84.00 252.00
Brain CAT scan 1 189.00 189.00
Abdomen CAT scan 1 226.00 226.00
Thorax CAT scan 1 226.00 226.00
Myocardial cintigrahy 11 450.00 4,950.00
ECG 211 18.00 3,798.00
AMBP 1 105.00 105.00
Treadmill 6 66.00 396.00
Spirometry 2 20.00 40.00
Echocardiogram 64 114.00 7,296.00
USE - Urinary sediment exam; HbA1c - Glycosylated hemoglobin; USG-
Ultrasonography; CAT scan - Computer-Aided Tomography; ECG-
Electrocardiogram; AMBP - Ambulatory monitoring of blood pressure
Table III - Total of direct and indirect costs
Results Amounts (R$)
Direct cost 224,775.24
Direct cost per patient/ 3,211.07 per patient/year
last 12 months
Average cost per patient 4,033.62 per patient/year
with hospitalization
Average cost per patient 1,191.86 per patient/year
with medications
Indirect cost 219,669.96
Indirect cost with 182,000.00
early retirement
Indirect cost per 37,669.96
working days missed
Total cost 444,445.20
Separation of direct %
cost per modalities
Hospitalization 39.73%
Medications 38.93%
Complementary exams 18.50%
Ambulatory appointments 2.84%
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press the lack of data on the real cost of chronic patients in SUS,
compromising the management of scarce funds available for the
public health system.
Early retirement and abstention show the importance of indirect
costs in the load of heart failure for the Brazilian society. Such
component of cost is frequently underestimated by the public health
policy formulators. The estimate of indirect cost in the studied
sample showed as important, quantitatively, as the direct cost.
The qualitative aspects for the society are even greater, as they
represent an early exit from the job market, with a big damage
for the self-esteem of the individual and need of social security
help. That scenario also took place in the American health system,
in 2001, when the CI-related indirect cost reached the amount
of US$ 53.6 billion and the direct cost was US$ 58.2 billion,
demonstrating the same quantitative impact11.
The separation of direct costs per types of use showed a finding
inconsistent with publications on the cost of heart failure. In the
studied sample, hospitalization accounted for 39.73% and the
use of medications 38.93%. A transversal study, based on preva-
lence of heart failure, during 1 year, carried out in the United
Kingdom12, showed that hospitalization contributed for 69% and
the use of medications was 18% from the total direct cost. Another
transversal study, based on prevalence of the syndrome, during a
year, carried out in Sweden13, revealed that hospitalization repre-
sented 74% and the use of medications accounted for 11% from
the total direct cost. The explanation for such difference can be
attributed to the lack of a pharmaceutical assistance program in
SUS, thus determining a financial burden to the patient, who
needs to purchase the medications from retailers, without any
power to trade.
Such finding reveals the need of implementation of a policy to
facilitate the access to chronic use medications in SUS, under
the risk of encumber, even more, the system with hospitalizations
arising from the lack of ambulatory medications.
The present study is an initiative aiming at making the many
actors in the system aware of the importance of the cost in decision-
making process in health, which contributes for a better allocation
of scarce funds, a greater access for the population to healthcare
services and a better quality of assistance to patients with heart
failure.
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